Valuation: PROT DIAG

Market Cap 240M 24.2M 21.27M 20.04M 18.31M 34.24M 2.32B 34.54M 93.19M 1.19B 90.87M 88.89M 3.87B P/E 2024
-2.94x
P/E 2025 -4.28x
Enterprise Value 200M 20.11M 17.68M 16.65M 15.22M 28.45M 1.93B 28.7M 77.44M 985M 75.51M 73.86M 3.22B EV / Sales 2024
2.16x
EV / Sales 2025 4.15x
Free-Float
12.26%
Yield 2024 *
-
Yield 2025 -
1 day+2.78%
1 week-9.16%
Current month+11.65%
1 month+14.07%
3 months+51.29%
6 months+7.78%
Current year+11.40%
1 week 19.4
Extreme 19.4
20.8
1 month 17.2
Extreme 17.2
23.35
Current year 12.46
Extreme 12.46
23.35
1 year 12.46
Extreme 12.46
23.35
3 years 11.7
Extreme 11.7
90.8
5 years 11.7
Extreme 11.7
169.5
10 years 11.7
Extreme 11.7
806
Manager TitleAgeSince
Chief Executive Officer 62 01/07/2020
Director of Finance/CFO 68 -
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Director/Board Member 70 01/01/2020
Director/Board Member 62 -
Director/Board Member 52 01/10/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%-9.16%-14.42%-74.50% 23.58M
+4.86%+9.45%+26.33%-16.55% 18.05B
-5.20%-1.65%-40.51%+23.38% 1.95B
-1.54%+1.16%-32.35%+22.85% 881M
+0.11%0.00%+52.02%-1.91% 778M
+3.38%-0.74%-61.04%-85.08% 709M
-0.69%+8.73%-29.95%-46.60% 691M
+1.77%+2.48%-36.80%-51.24% 579M
+5.30%+16.13%+52.58%+90.73% 452M
-0.95%+1.96%-6.83%+0.85% 404M
Average +0.98%+3.04%-9.10%-13.81% 2.45B
Weighted average by Cap. +3.32%+3.65%+14.01%-12.93%

Financials

2024 2025
Net sales 36.33M 3.66M 3.22M 3.03M 2.77M 5.18M 351M 5.22M 14.1M 179M 13.74M 13.44M 586M 42.2M 4.25M 3.74M 3.52M 3.22M 6.02M 408M 6.07M 16.37M 208M 15.97M 15.62M 680M
Net income -26.94M -2.71M -2.39M -2.25M -2.05M -3.84M -260M -3.87M -10.45M -133M -10.19M -9.97M -434M -49.71M -5.01M -4.4M -4.15M -3.79M -7.09M -481M -7.15M -19.29M -245M -18.81M -18.4M -801M
Net Debt -15.73M -1.59M -1.39M -1.31M -1.2M -2.24M -152M -2.26M -6.11M -77.65M -5.95M -5.82M -254M -40.61M -4.09M -3.6M -3.39M -3.1M -5.79M -393M -5.84M -15.76M -200M -15.36M -15.03M -655M
Logo PROT DIAG
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Employees
22
Date Price Change Volume
24/09/26 SEK 19.94 +2.78% 10,873
23/09/26 SEK 19.40 -6.73% 11,919
22/09/26 SEK 20.80 +6.45% 13,338
21/09/26 SEK 19.54 +0.31% 7,227
18/09/26 SEK 19.48 -6.35% 43,075
  1. Stock Market
  2. Stocks
  3. PRLD Stock